Endo eyes a deal for Somerset and Wintac

Endo is set to augment the firm’s commercial portfolio and pipeline of generic sterile injectables and ophthalmic drugs, as well as bolster its manufacturing capabilities, after agreeing to acquire New Jersey based Somerset Therapeutics and its contract development and manufacturing business, India’s Wintac, for around US$190 million.